Microbial cell factories offer an attractive approach for production of biobased products.
Introduction
For decades, scientists and engineers have turned to biological systems to help meet societal needs in energy, medicine, and materials-especially when chemical synthesis is untenable (e.g., antimalarial drugs). Often, biologically-produced small molecules are insufficient for production at the optimal titer, rate, or yield because natural sources are difficult to optimize and may not scale easily (e.g., plants grow slowly). Thus, engineers seek to design enzymatic reaction schemes in model microorganisms to meet manufacturing criteria. 1 Success in these endeavors depends upon identifying sets of enzymes that can convert readily available molecules (e.g., glucose) to high-value products (e.g., medicines), with each enzyme performing one of a series of chemical modifications. Unfortunately, this is difficult because design-build-test (DBT) cycles-iterations of re-engineering organisms to test new sets of enzymes-are detrimentally slow. 2, 3 As a result, a typical project today might only explore dozens of variants of an enzymatic reaction pathway. This is often insufficient to identify a commercially relevant solution because selecting productive enzymes using existing single-enzyme kinetic data has limited applicability in multi-enzyme pathways and consequently requires more DBT iterations. 4 This challenge is exacerbated in industrially-relevant, non-model organisms (such as clostridia) for which genetic tools are not as sophisticated, high-throughput workflows are often lacking, there exist transformation idiosyncrasies, and there is reduced availability of validated genetic parts.
Yet, many industrial bioprocesses (e.g., synthesis of amino acids, 5 organic acids, [6] [7] [8] solvents 9,10 ) rely on non-model organisms as they offer exceptional substrate and metabolite diversity, as well as tolerance to metabolic end-products and contaminants, making them excellent chassis for biochemical production of exotic molecules from an array of possible feedstocks. Clostridia specifically were used industrially in acetone-butanol-ethanol (ABE) fermentations in the early-to-mid 20 th century because of their unique solventogenic metabolism to produce large amounts of solvents (e.g., acetone and butanol) but were eventually phased out of use due to the success of petroleum until recently. 11 In addition, cellulolytic clostridia can degrade lignocellulosic biomass and acetogenic clostridia can robustly ferment on a variety of abundant, low-cost C1 gases including waste gases from industrial sources (e.g., steel mills, processing plants or refineries) or syngas generated from any biomass resource (e.g., municipal solid waste or agricultural waste). 12 Acetogenic clostridia have recently proven industrial relevance for full commercial scale ethanol production using emissions from the steel making process. 13 However, these strains tend to lack the natural machinery to produce such solvents or other more complex products, and the tools to engineer them are underdeveloped with the solutions established for E. coli and yeast not being directly transferrable. 14 In fact, until a few years ago, Clostridium organisms were considered genetically inaccessible with only a handful of genomic modifications being reported. 15, 16 While developing tools for engineering Clostridium is ongoing and promising progress has been made, 17, 18 discovering methods to speed up metabolic engineering DBT cycles for these organisms would accelerate the re-industrialization of such organisms. 14, 19 Cell-free systems provide many advantages for accelerating DBT cycles. [20] [21] [22] For example, the open reaction environment allows direct monitoring and manipulation of the system to study pathway performance. As a result, many groups have used purified enzyme systems to study enzyme kinetics and inform cellular expression: testing enzymatic pathway performance in vitro, down-selecting promising pathway combinations, and implementing those in cells. 20, [23] [24] [25] [26] Crude lysates are becoming an increasingly popular alternative to purified systems to build biosynthetic pathways because they inherently provide the context of native-like metabolic networks. [27] [28] [29] For instance, the Panke group has shown that DHAP can be made in crude lysates and real-time monitoring can optimize production. 29 In addition, our group has shown that 2,3-butanediol, 30 mevalonate, 28 n-butanol, 27, 31 limonene, 32, 33 and more complex products 34 can be constructed in crude lysates with high productivities (>g/L/h). However, to our knowledge, no attempts have been made using cell-free prototyping to improve engineering of industrially-relevant, non-model organisms.
To address this opportunity, we report a new in vitro Prototyping and Rapid Optimization of Biosynthetic Enzymes approach (termed iPROBE) to inform cellular metabolic engineering.
The foundational principle is that we can construct discrete enzymatic pathways through modular assembly of cell lysates containing enzymes produced by cell-free protein synthesis rather than by living organisms (Figure 1) . This reduces the overall time to build pathways from weeks (or even months) to a few days, providing an increased capability to test numerous pathways by avoiding inherent limitations of cell growth and thus diminishing the reliance on single-enzyme kinetic data. A key conceptual innovation is that the DBT unit can be cellular lysates rather than genetic constructs, allowing us to perform DBT iterations without the need to re-engineer organisms. The rapid ability to build pathways in vitro using iPROBE allows us to generate large amounts of data describing pathway operation under several operating conditions. We demonstrate iPROBE in two ways. First, we use a new quantitative ranking system to bridge cellfree data and cellular metabolic engineering for the production of 3-hydroxybutyrate (3-HB) in Clostridium autoethanogenum from C1 gas. Specifically, we tested 54 different enzyme combinations for 3-HB and identify pathway combinations that produce at high-titers in vivo. The work also led to identification of a new route to (S)-(+)-1,3-butanediol (1,3-BDO), both non-native products for acetogenic clostridia and to our knowledge the first demonstration for biological production of the (S)-(+)-isomer of 1,3-butanediol. Second, we show the utility of iPROBE by increasing cell-free n-butanol production ~4-fold in less than two weeks by assessing performance of 205 pathways using data-driven design-of-experiments. We then selected 9 pathway combinations from the iPROBE screen to assess butanol production in C. autoethanogenum strains, observing a strong correlation (r 2 > 0.9) between in cell and cell-free pathway performance.
Figure 1. A two-pot cell-free framework for in vitro prototyping and rapid optimization of biosynthetic enzymes (iPROBE).
A schematic overview of the iPROBE approach following a DBT and apply framework is depicted. In the design phase, reaction schemes and enzyme homologs are selected. In the build phase, lysates are enriched with pathway enzymes via overexpression prior to lysis or by cell-free protein synthesis post lysis. Then, lysates are mixed to assemble enzymatic pathway combinations of interest. In the test phase, metabolites are quantified over time and data is reduced into a single quantitative metric for pathway combination ranking and selection. In the apply phase, cell-free pathway combinations are selected and implemented in cellular hosts.
Results

Establishing a two-pot, cell-free framework for pathway prototyping
We selected 3-hydroxybutyrate (3-HB) biosynthesis as a prime example for pathway prototyping with iPROBE given it is non-native to clostridia and its importance as a high-value specialty chemical. 35, 36 Our vision was to demonstrate modular assembly of the pathway by mixing (Figure 1) . A unique feature of the iPROBE approach, relative to previous works in crude lysate-based cell-free prototyping, 27, [31] [32] [33] 37 is that pathways are assembled in two steps (i.e., 2 pots), where the first step is enzyme synthesis via cell-free protein synthesis (CFPS) and the second step is enzyme utilization via substrate and cofactor addition to activate small molecule synthesis. Separating enzyme synthesis and utilization into two separate pots enables the modular control of enzyme concentrations because exact amounts can be added to the biosynthetic reaction. Moreover, negative physiochemical effects of the CFPS reaction 31 on small molecule biosynthesis can be reduced.
We first set out to use iPROBE to study the impact of enzyme stoichiometry on pathway performance for the two, non-native enzyme pathway to 3-HB (Figure 2A) . A thiolase (Thl) and a hydroxybutyryl-CoA dehydrogenase (Hbd), along with a native thioesterase, 38 are required to make 3-HB. We initially selected a Thl gene from Clostridium acetobutylicum (Cac) and a Hbd gene from Clostridium kluyveri (Ckl) ( Supplementary Table S1 ). We used the well-characterized E. coli-based PANOx-SP CFPS system 39 Figure S1 ). Taken together, our data show that crude lysates enriched by CFPS can be used to assemble metabolic reactions and sets the stage to optimize pathways using a two-pot cell-free approach. 
Developing a metric to quantify biosynthetic pathway performance
To optimize pathways with iPROBE, we next defined a pathway ranking system that would enable assessment of activity in the cell-free environment and hold potential to inform cellular design. The basis of this ranking system is a single, quantitative metric for our cell-free experiments. We call this metric the TREE score (for titer, rate, and enzyme expression; important metrics for defining the success of cell-based metabolic engineering). The TREE score combines, e Pathway Combination through multiplication, titer at reaction completion, rate during the most productive phase of pathway operation, and enzyme expression as measured by protein solubility and total enzyme amount. Using our initial set of data (Figure 2 ) as a guide, the TREE score is obtained by multiplying 3-HB titer at 24 h, the linear 3-HB production rate between 3 and 6 h, and the sum of the average solubility of the pathway enzymes, Thl and Hbd, and the inverse of the total enzyme concentration for each of the five pathway combinations (Supplementary Figure S2; Figure 2E ).
While the TREE score rankings are not drastically different from the titers or rates alone, which they should not be, they exaggerate differences that might arise from each component of the score. Combining titer and rate enables use of both in ranking cell-free pathway performance which is helpful as it is unknown whether cell-free titer or rate is more or less important for informing cellular metabolic engineering. Incorporating enzyme expression allows pathways that have expression difficulties to decrease the overall pathway rank so as to avoid enzymes with poor expression properties. By reducing the complexity of available cell-free data to one value, the TREE score enables a rapid approach to rank pathways for iPROBE.
iPROBE informs selection of genetic regulatory architectures in Clostridium
With a pathway ranking system at hand, we next aimed to validate that cell-free experiments could generate design parameters for DNA construction of biosynthetic pathways in cells. Gene expression involves designing a coding sequence, 5' and 3' regulatory elements, and vector maintenance components, among other parts. Selection of the promoter regulatory strengths (e.g., high, medium, low) for the expression of a coding sequence, in particular, is an essential factor for pathway tuning. Thus, we set out to develop a correlation between specific enzyme concentrations in iPROBE and specific strength regulatory architectures, relative promoter strengths and plasmid copy number for a single operon comprising the 3-HB pathway, for expression in C. autoethanogenum. To achieve this goal, we built cell-free pathway combinations for 3-HB by co-titrating seven different enzyme concentrations of Thl and Hbd in our reactions (Supplementary Figure S3 ). Specifically, we built seven cell-free reactions in increasing total concentration added, combining CacThl and CklHbd at equimolar amounts. We ran each cell-free reaction for 24 h and measured the titer of 3-HB produced (Supplementary Figure S3C ). We observed that as the amount of enzyme added increases, the amount of 3-HB increased up to a threshold amount of 1 µM of each enzyme added. In parallel, we constructed plasmids expressing CacThl and CklHbd under eight regulatory architectures (change in promoter strength and plasmid copy number) of increasing strength and transformed them into separate strains of C. autoethanogenum. We ran small-scale bottle fermentations of each strain under anaerobic conditions on carbon monoxide (CO), hydrogen (H2), and carbon dioxide (CO2) gas and measured stationary phase titers of 3-HB (Supplementary Figure S3D ) and observed a similar trend to the cell-free studies. Namely, we found that increases in expression strength led to higher 3-HB titers. These data allowed us to build a cell-free to cell correlation that connects cell-free 3-HB production and corresponding enzyme concentrations to cellular 3-HB production and corresponding plasmid regulatory strength. We found that using < 0.1 µM enzyme in vitro corresponds to low regulatory strengths in vivo, using 0.1 -0.3 µM enzyme in vitro corresponds to medium strengths in vivo, and using > 0.3 µM enzyme in vitro corresponds to high strengths in vivo. In principle, this allows us to screen many different pathway combinations in cell-free systems and provide a rational recommendation for plasmid construction of those pathway combinations in Clostridium, which is what we did next.
iPROBE can inform the selection of pathway enzymes in Clostridium
To showcase the iPROBE approach, we next screened several possible 3-HB pathway combinations using cell-free experiments, ranked a subset of candidate cellular pathway combinations using the TREE score, and showed cellular C. autoethanogenum 3-HB biosynthesis from CO/H2/CO2 gas correlates with cell-free experimental results. To do this, we tested six enzyme homologs of each Thl and Hbd originating from different Clostridium species (Figure 3A ; Supplementary Table S1 ). We selected all pathway combinations of the 12 enzymes keeping a fixed total concentration of enzyme added (high expression levels) to build in cell-free reactions (Figure 3B-C) . By measuring 3-HB production over the course of 24 h along with soluble enzyme expression for each of the enzymes (Supplementary Figure S4) , we are able to calculate TREE scores for each of the 36 pathway combinations (Figure 3D) . We found that a majority of pathway combinations perform poorly with only a handful achieving TREE scores above a value of 2. We wanted to use this information to down-select the number of combinations to test in acetogenic clostridia due to the current limitations in high-throughput strain testing. We selected a subset of four pathway combinations from the iPROBE screening to test in C. autoethanogenum labeled A, B, C, and D. We constructed and transformed DNA with strong regulatory architectures and each of the four-pathway enzyme sets into separate strains of C. autoethanogenum (Figure 3E) . We ran small-scale bottle fermentations of each strain under anaerobic conditions on CO/H2/CO2 gas mixture and measured 3-HB titers at four time-points during the fermentation (Figure 3F) . We observed that the best cell-free pathway combination as determined by TREE score (D) also performs the best of the four in Clostridium cells, achieving 33.33 ± 1.44 mM. The worst pathway combination in cell-free experiments (A) is also the worst performer in C. autoethanogenum. The other two pathway combinations (B, C), which were not statistically different, fall in the middle in cellular experiments. At a high-level, these data suggest that the cell-free system is useful for guiding pathway selection in cells. This might be especially true for down-selecting pathway combinations that should not be tested in cells (i.e., produce little to no product). In fact, the best pathway designs tested in two recent studies that explored autotrophic 3-HB production in acetogenic clostridia produced ~4 mM and ~1 mM 3-HB. 41, 42 Their pathways correspond to TREE scores of 1.06 ± 0.07 and 0.02 ± 0.00, respectively. Based on our iPROBE screening we would have suggested not testing these combinations in vivo. For context, our best pathway had a TREE score of 17.76 ± 3.08. In sum, iPROBE offers a framework to rapidly design, build, and test pathway combinations in cell-free experiments in a matter of days, bypassing DNA construction and transformation limitations, and to facilitate implementation of promising pathway combinations for engineering success in cells.
Figure 3. Enzymatic pathways can be screened with iPROBE to inform Clostridium expression for optimizing 3-hydroxybutyrate production.
A reaction scheme for the production of 3-HB is presented in panel (a). Six homologs have been selected for each reaction step. The design in (b) includes the testing of six Thl homologs and six Hbd homologs at 0.5 µM each. We built each possible combination in cell-free systems (c) constituting 36 unique pathway combinations. We rapidly built these cell-free pathways by expressing each of the 12 enzyme variants in lysates by CFPS. We then mixed each to try all 36 possible combinations keeping enzyme concentration fixed. (d) 3-HB was measured, and TREE scores were calculated and plotted for each iPROBE pathway combination with propagated error. We then selected four pathway combinations to test in C. autoethanogenum (A, B, C, and D). These pathways were built in high copy plasmids with the highest strength promoters in single operons (e). Clostridium strains containing these pathway combinations were then fermented on gas and 3-HB was measured over the course of fermentation (f). Error bars represent technical triplicates.
Scaled-up fermentations of 3-HB pathway prototype
We next coupled the results of our integrated iPROBE approach with in-house facilities to scale cell growth from bench to continuous fermentation scales ( Figure 4A) . Specifically, the best performing strain for 3-HB production selected by iPROBE was chosen for process scale-up from 0.1-L bottle fermentations to 1.5-L continuous fermentations using CO/H2/CO2 gas as the sole carbon and energy source. Over a 2-week fermentation, we monitored 3-HB and biomass in a control strain and our iPROBE-selected strain with and without optimized fermentation conditions ( Figure 4B-C) . In optimized fermentations we observed high-titers of 3-HB, ~15 g/L (140 mM) at rates of >1.5 g/L/h in a continuous system. This is not only higher than the previously reported concentration in acetogenic Clostridium, 41, 42 but to our knowledge also exceeds the previously highest-reported concentration for traditional model organisms like E. coli (titer of ~12 g/L and rate of ~0.25 g/L/h in fed-batch) 38, 43 and yeast (titer of ~12 g/L and rate of ~0.05 g/L/h in fedbatch) 44 without any additional genomic modifications to optimize flux into the pathway. This shows the utility of iPROBE in identifying pathways for industrial strain development. We anticipate that genome modifications to increase flux could further improve fermentation titers.
For example, a recent study reported a 2.6-fold improvement in 3-HB production in a related engineered acetogenic Clostridium by downregulation of two native genes related to acetate production. 42 Surprisingly, we also observed production of a novel metabolite, 1,3-butanediol (1,3-BDO), at 3-5% of the 3-HB levels and up to 0.5 g/L (Figure 4D) . This is attributed to nonspecific activity of a native aldehyde:ferredoxin oxidoreductase (AOR) and alcohol dehydrogenase able to reduce 3-HB to 3-hydroxybutyraldehyde and further to 1,3-BDO. Indeed, no 1,3-BDO was observed when transforming the pathway into a previously generated AOR-knockout strain. 45 These enzymes have previously been shown to reduce a range of carboxylic acids to their corresponding aldehydes and alcohols through reduced ferredoxin. 15, 46 While the (R)-(-)-form of 1,3-BDO has been produced via other routes, [47] [48] [49] when using the C. kluyveri-derived Hbd we also detected the (S)-(+)-form of 1,3-BDO as determined by chiral analysis, which to our knowledge has never been produced in a biological system before. This chiral specificity is determined by the chosen 3-hydroxybutyryl-CoA dehydrogenase. Given that 1,3-BDO is used in cosmetics and can also be converted to 1,3-butadiene used in nylon and rubber production with a US$20
billion/year market, 35 ,50 the discovery of this pathway is important. In sum, iPROBE provides a quick and powerful DBT framework to optimize and discover biosynthetic pathways for cellular metabolic engineering efforts, including those in non-model hosts.
Cell-free pathway prototyping for n-butanol biosynthesis
Having demonstrated the use of iPROBE to optimize the 3-HB pathway for informing cellular design in C. autoethanogenum, we next aimed to show that iPROBE could be used to optimize longer pathways. We selected the 6-step pathway from acetyl-CoA to nbutanol as a model pathway for this because butanol is an important solvent and drop-in fuel with US$5
billion/year market (Figure 5A) . The key idea was to use iPROBE to optimize cell-free butanol production by constructing pathway variants with different enzyme homologs and reaction stoichiometry. The challenge with this optimization goal is the number of possible permutations.
Indeed, testing just six homologs for each of the first four steps of the pathway at three different enzyme concentrations would alone require 314,928 pathway combinations, which exceeds typical HPLC analytical pipelines. Nevertheless, we know that homolog changes and reaction stoichiometry should be optimized simultaneously because tuning stoichiometries of one set of enzymes (EcoThl, CbeHbd, CacCrt, and TdeTer; Figure 5A , highlighted in blue) does not achieve significant improvements (Supplementary Figure S5) . To optimize enzyme homologs and concentrations simultaneously while also managing the landscape of testable hypotheses, we implemented a design-of-experiments using a neural-network-based algorithm to predict beneficial pathway combinations. This approach requires an initial data set to seed and train the neural networks.
In creating the initial data set to guide improvements in titer, we chose six homologs of each Thl, Hbd, Crt, and Ter (Supplementary Table S1; Figure 5A ). We tested five reaction stoichiometries for each enzyme homolog in a pathway context consisting of our base set of enzymes (Figure 5A , highlighted in blue), totaling 120 pathway combinations, including those in Supplementary Figure S5 . We built these combinations in cell-free reactions from enzymes produced by CFPS, measured butanol production over time, and calculated TREE scores for each ( Figure 5B; Supplementary Figure S6) . In total, we collected these additional data in five experimental sets of 20 pathway combinations with each set taking five days (three days of HPLC time). A majority of the enzyme homologs did not out-perform the original enzyme set. This is not surprising as the base case has been extensively characterized and tested throughout the literature. [51] [52] [53] However, we find that CklHbd1 can double the TREE score at high concentrations and even out-performs the base case Hbd at lower concentrations. This agrees with an independent study that found a 1.6-fold improvement in ABE fermentation with C. acetobutylicum by replacing the native Hbd with the CklHbd1. 54
Figure 5. Cell-free pathway testing combined with data-driven design-of-experiments quickly screens 205 unique pathway combinations and selects pathways for cellular butanol production. A reaction scheme for the production of butanol is presented in panel (a).
Six homologs have been selected for each of the first four reaction steps and are shown in panel (a). (b) The strategy for running an initial set of reactions is to test each homolog at 5 concentrations individually with the base case set of enzymes (blue). These 120 pathway combinations are run in cell-free reactions according to the two-pot iPROBE methodology and TREE scores are calculated from 24-h butanol time-courses. The dashed line is placed at the TREE score resulting from the base case set of enzymes. (c) Neural-network-based design of experiments is implemented using the data presented in (b) to predict enzyme sets and concentrations to be constructed. (d) These are then built in cell-free systems. TREE scores are calculated for all newly tested pathway combinations from 24-h butanol time-courses. The black dashed line is placed at the TREE score resulting from the base case set of enzymes, the grey in vitro TREE Score dashed line corresponds to the TREE score of the best case from (b), and the orange dashed line represents the highest TREE score achieved through the data-driven iPROBE approach. (e) Nine pathway combinations (two high-performing pathways, two medium-performing pathways, and five low-performing pathways) were constructed and transformed in vivo in C. autoethanogenum. End-point titers of butanol production (relative to the highest in vivo titer) are plotted against in vitro TREE scores for the corresponding pathway combination. Error bars for in vivo titers are relative standard deviations for four to six replicates. Error bars for all TREE scores are propagated error based on TREE score calculations.
With this initial dataset collected (Figure 5B) , we used ten randomly generated, trained, and evaluated neural network architectures to make pathway combination predictions (homolog set and reaction stoichiometry) to maximize TREE score which we could then build with the cellfree framework (Figure 5C ). Design predictions suggesting enzyme concentrations of < 0.01 µM were ruled out, and we built the remaining 43 predictions in cell-free reactions (Supplementary Figure S7A) . To evaluate our design-of-experiments approach, we compared the results with two additional sets of experiments: (i) a set varying reaction stoichiometry more thoroughly using only the base set enzymes (21 pathway combinations; Supplementary Figure S7B) and (ii) a handselected set of 18 pathway combinations based on our understanding of the biosynthesis (Supplementary Figure S7C ). In total we tested 205 unique pathway combinations (base set combinations, initial round combinations, and data-driven designs) (Figure 5D; Supplementary   Figure S6 ). Nearly 19% of the total pathway combinations screened have higher TREE scores than our base case. Without testing every possible combination, we were able to rapidly test a manageable subset achieving ~4 times higher TREE scores (~2.5 times higher titer and 58% increase in rate) over the base case pathway combination. The top six TREE scores each arose from pathways predicted in the neural-network-based design, showcasing the importance of merging computational and experimental design. Further analysis of the pathway combinations shows that there are enzyme homologs and concentrations that clearly improve the TREE score.
The chosen thiolase does not seem to matter in the 20 top-performing combinations whereas the C. kluyveri Hbd1 is far superior to other Hbd enzymes (Supplementary Figure S8A) . We also noticed that in the 20 top-performing combinations Hbd is present at significantly (p<0.001) higher concentrations and the median Crt concentration is lower, though not significantly, than the initial 0.3 µM (Supplementary Figure S8B) . This suggests that optimal pathway operation occurs when enough flux can pass away from central carbon metabolism down the butanol pathway but minimal flux flows through the toxic intermediate metabolite, crotonyl-CoA.
We next assessed iPROBE's ability to enhance cellular design by selecting nine representative pathway combinations from the iPROBE screening and constructing them in C. autoethanogenum strains to produce butanol: two pathway combinations scoring among the top five combinations, two pathway combinations in the middle range of the data set, and five pathway combinations near the tail-end of all combinations tested. To avoid diverting flux toward 3-HB, we identified and knocked-out a native thioesterase able to hydrolyze 3-HB-CoA from our screening strain. After monitoring butanol production over the course of six days (Supplementary Figure   S9A) , we see a high correlation (r 2 = 0.93) between in vivo expression in C. autoethanogenum and TREE scores from iPROBE (Figure 5E) . This further emphasizes that selecting topperforming pathways from iPROBE can improve production in Clostridium organisms and decreases the number of strains that need to be tested. While overall butanol production was low in C. autoethanogenum using the iPROBE-selected pathways, we were able to increase production over 200-fold from 0.1 ± 0.0 mM to 22.0 ± 1.3 mM (Supplementary Figure S9B) by replacing the trans-2-enoyl-CoA reductase (Ter) enzyme with the ferredoxin-dependent electron bifurcating enzyme complex (Bcd-EtfA:EtfB) naturally used for these activities in clostridia. 55 This is not surprising in light of a recent study that showed Ter is detrimental to ABE fermentation when introduced in C. acetobutylicum. 56 For comparison, the previously best reported butanol production in engineered acetogenic clostridia was ~2 mM. 15 Moreover, the Bcd-EtfA:EtfB complex is a delicate complex that is extremely oxygen sensitive 57 and has so far been inactive in E. coli lysates (in alignment with previous reports that highlighted difficulties expressing Bcd in E. coli), 52 highlighting an area for potential improvement of iPROBE (i.e., compatibility of E. coli lysates with non-model organisms). Overall, this work demonstrates the power of coupling data-driven design-of-experiments with a cell-free prototyping framework to select feasible subsets of pathways worth testing in vivo for non-model organisms.
Conclusion
We demonstrate a new, two-pot framework, iPROBE, that incorporates a highly controllable and modular cell-free platform for constructing biosynthetic pathways with a quantitative metric for pathway performance selection (the TREE score) to engineer and improve small molecule biosynthesis in non-model organisms that can be arduous to manipulate.
Specifically, we show that by screening 54 biosynthetic pathway combinations for the production of 3-HB in cell-free reactions, we can rationally select a handful of pathways to inform cellular metabolic engineering in clostridia. Indeed, iPROBE enabled the construction of a strain of C.
autoethanogenum that produces high-titers and yields of 3-HB (~20x higher than the previous highest reported concentration in the literature) in continuous fermentations with carbon monoxide/hydrogen/carbon dioxide gas as sole source of carbon and energy. The work also led to the identification of a new route to 1,3-BDO and the first production to our knowledge of the (S)-isomer of this molecule in a biological system. Beyond the 3-HB example, we also show the ability to use iPROBE in conjunction with data-driven design-of-experiments to reduce an exceedingly large landscape of testable pathway designs, test a subset of 205 pathway combinations in vitro for the production of butanol, and show that by testing a further subset of designs in vivo we can improve butanol production in acetogenic clostridia. Highlighting the utility of iPROBE for accelerating DBT cycles, the 205 pathway combinations for butanol were built cumulatively in 12 days (excluding HPLC time) in cell-free reactions, which we estimate would have taken a team of researchers more than 3 months in clostridia. Importantly, we show that there is indeed a correlation between pathway performance in vitro and in vivo providing evidence of the effectiveness of the iPROBE approach.
Looking forward, we anticipate that iPROBE will facilitate DBT cycles of biosynthetic pathways by enabling the rapid study of pathway enzyme ratios, tuning individual enzymes in the context of a multi-step pathway, screening enzyme variants for high-performance enzymes, and discovering enzyme functionalities. This in turn will decrease the number of the strains that need to be engineered and time required to achieve desired process objectives. This will increase the flexibility of biological processes to adapt to new markets, expand the range of fossil-derived products that can be displaced with bio-derived alternatives, and enhance the economic benefits for co-produced fuels.
Methods
Bacterial strains and plasmids
Escherichia coli BL21(DE3) (NEB) was used for preparation of cell extracts which were used to express all exogenous proteins in vitro. 37 A derivate of Clostridium autoethanogenum DSM10061 obtained from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ; Braunschweig, Germany) was used for in vivo characterization and fermentations. 58 For butanol production, this strain was used with a native thioesterase (CAETHG_1524) knockout made using Triple Cross recombination as described previously. 59 Twenty-three enzymes were examined in this study ( Supplementary Table S1 ). DNA for all enzyme homologs tested were codon adapted for E. coli using IDT codon optimizer. Nonclostridial sequences were codon adapted for C. autoethanogenum using a LanzaTech in-house codon optimizer, and all native clostridial genes were used as is. E. coli and C. autoethanogenum adapted sequences are listed in Supplementary Table S2 and Supplementary Table S3 , respectively. For the cell-free work, the pJL1 plasmid (Addgene #69496) was used. The modular pMTL80000 plasmid system 60 along with acsA 45 , fdx 45 , pta 61 and pfor 62 promoters were used for the C. autoethanogenum plasmid expression.
Cell Extract Preparation
E. coli BL21(DE3) cells were grown, harvested, lysed, and prepared using previously described methods. 27, 63 iPROBE Reactions Cell-free protein synthesis (CFPS) reactions were performed to express each enzyme individually using a modified PANOx-SP system described in previous pubications. 39, 64 Fifty-μL CFPS reactions were carried out for each individual enzyme in 2-mL microcentrifuge tubes. Enzyme concentrations in CFPS reactions were quantified by 14 C-leucine incorporation during in vitro translation. Then reactions performed for identical enzymes were pooled together when multiple reaction tube-volumes were needed to keep a consistent 50-µL reaction volume and geometry for every CFPS reaction. Based on molar quantities of exogenous enzymes in each CFPS reaction determined by radioactive measurement, CFPS reactions were mixed to assemble complete biosynthetic pathways in 1.5-mL microcentrifuge tubes. CFPS reactions constitute 15 µL of a 30-µL-total second reaction. When the total CFPS reaction mixture constituted less than 15 µL, 'blank' CFPS reaction was added to make the total amount of CFPS reaction up to 15 µL.
The 'blank' reactions consist of a typical CFPS reaction with no DNA added. This 15 µL CFPS mixture was then added to fresh extract (8 mg/mL), kanamycin (50 μg/ml), glucose (120 mM), 
Quantification of protein produced in vitro
CFPS reactions were performed with radioactive 14 C-Leucine (10 µM) supplemented in addition to all 20 standard amino acids. We used trichloroacetic acid (TCA) to precipitate radioactive protein samples. Radioactive counts from TCA-precipitated samples was measured by liquid scintillation to then quantify soluble and total yields of each protein produced as previously reported (MicroBeta2; PerkinElmer). 39, 40 
Metabolite Quantification
High-performance liquid chromatography (HPLC) was used to analyze 3-HB and n-butanol. We used. Samples were prepared by heating for 5 minutes at 80 °C, followed by a 3-minute centrifugation at 14,000 rpm. Exactly 400 µL of supernatant was then transferred to a 2-mL glass autosampler vial and 100 µL of and Internal Standard solution (5-methyl-1-hexanol and tetrahydrofuran in ethanol) was added. The capped vial was then briefly vortexed. Sample vials then were transferred to an autosampler for analysis using a 1.0 µL injection, a split ratio of 60 to 1, and an inlet temperature of 230 °C. Chromatography was performed with an oven program of 50 °C with a 0.5 min hold to a ramp of 3 °C/min to 70 °C to a ramp of 2 °C/min to 100 °C with a final ramp at 15 °C/min to 220 °C with a final 2-min hold. The column flow rate was 30 cm/sec using helium as the carrier gas. The FID was kept at 230 °C. Quantitation was performed using a linear internal standard calibration.
TREE Score Calculations
The TREE Score is calculated by multiplying the titer by the rate by enzyme expression metric.
The titer is the metabolite concentration in the cell-free reaction at 24 h, when the reaction is 
In vivo Gas Fermentations
In vivo cultivation and small-scale bottle fermentation studies were carried out as described earlier using a synthetic gas blend consisting of 50% CO, 10% H2, 40% CO2 (Airgas, Radnor, PA). 62 Continuous fermentations were carried out in 1.5L continuous stirred tank reactors (CSTRs) with constant gas flow as described elsewhere. 65, 66 
Design-of-experiments using neural networks
A neural network-based approach was used to explore the vast landscape of possible experimental designs. The neural networks, which were all designed as deep neural network regressions, had between 5 and 15 layers and between 5 and 15 nodes in each layer. We randomly generated the network architectures, which we then evaluated based on how accurately the trained models predicted the training data. We trained and evaluated 500 unique network architectures and selected the top 10. Modeling enzymatic pathways requires a mix of continuous and categorical variables. Because many machine learning algorithms require numeric input and output variables, we used one-hot encoding, which is a process that converts categorical variables into a numerical form that machine learning algorithms can use. This method treats categorical variables as a multidimensional binary input that must sum to one. The concentration values were used as is, resulting in a 30 variable input matrix: 25 variables representing the categorical variation (i.e., different homologs) and 5 representing the concentration. Ten predictions were selected from each of the top 10 architectures and then we removed predictions that were impossible experimentally (i.e., concentrations too low to pipet accurate volumes).
Statistics
All error bars on metabolite and protein quantification represent one standard deviation derived from technical triplicates. All error bars on TREE score values are propagated error as described in the TREE score calculation. In comparing the significance of enzyme concentration on TREE scores for butanol production in Supplementary Figure 8B we used the Mann-Whitney test to determine whether enzyme concentrations of the enzyme combinations that produced the top 20 TREE scores are greater than the enzyme concentrations of the entire data set.
Data and Materials Availability
All cell-free data generated and shown in this manuscript are provided in Supplementary File A (.xlsx). Any additional data or unique materials presented in the manuscript may be available from the authors upon reasonable request and through a materials transfer agreement.
Supplementary Figure S2 . The titer, rate, and enzyme expression (TREE) score is calculated through multiplication. 3-hydroxybutyrate is measured at 0, 3, 4, 5, 6, and 24 h after the addition of glucose for each of the five pathway combinations described in . We built these seven designs in cell-free systems (c) by CFPS of each enzyme in separate lysates (Pot #1) followed by mixing to assemble full pathways for 3-HB production (Pot #2). We measured 3-HB over the course of 24 h for each. We compared these results to Clostridium-based expression by building eight genetic constructs with varying promoters and plasmid copy number (e). We measured 
